source
- J&J invests $785M in Sail Biomedicines, secures option to buy for $2.58BJohnson & Johnson has agreed to pay $785 million up front to Sail Biomedicines, including a $465 million equity infusion and up to $140 million in milestone payments. The agreement also gives J&J a…
- Biopharma layoffs in 2026 often marred by impersonal and poorly timed communicationsOver 50 biopharma companies have announced workforce cuts or plan to do so in 2026. According to a BioSpace survey, the manner in which these layoffs are communicated can leave a lasting negative i…